Literature DB >> 2544988

Differential sensitivities of purified human eosinophils and neutrophils to defined chemotaxins.

E Morita1, J M Schröder, E Christophers.   

Abstract

Functions of eosinophils and neutrophils isolated from normal human blood were determined by measuring chemotactic migration and release of beta-glucuronidase. Four well-characterized chemotaxins, the complement fragment C5a, formyl-methionyl-leucyl-phenylalanine (FMLP), platelet-activating factor (PAF), and leukotriene B4 (LTB4) were used as stimuli. Neutrophils showed remarkable chemotactic responses to all four chemotaxins. In contrast, eosinophils showed a significant chemotactic response to C5a and PAF, but only weak responses to FMLP and LTB4. Using these chemotaxins we found the following order of chemotactic potency (maximal number of migrated cells): C5a = LTB4 greater than FMLP greater than PAF for neutrophils and PAF = C5a greater than LTB4 = FMLP for eosinophils. Neutrophils elicited a significant beta-glucuronidase release when stimulated by C5a and FMLP, whereas only small amounts were released with PAF and LTB4. On the other hand, an amount of beta-glucuronidase released from eosinophils comparable to that from neutrophils was elicited only with C5a. FMLP, LTB4, and PAF caused the release of small percentages of beta-glucuronidase. The important cellular functions of eosinophils and neutrophils, chemotaxis and enzyme release, are thought to be controlled by differential responsiveness to stimuli.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2544988     DOI: 10.1111/j.1365-3083.1989.tb01175.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  13 in total

Review 1.  Complement: an overview for the clinician.

Authors:  Juan Carlos Varela; Stephen Tomlinson
Journal:  Hematol Oncol Clin North Am       Date:  2015-04-04       Impact factor: 3.722

2.  The role of histamine in the acute inflammatory responses to intradermal platelet activating factor.

Authors:  D G Sciberras; S Jordan; D Gill; N S Baber; I James
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

3.  Airway epithelial cells synthesize the lipid mediator 5-oxo-ETE in response to oxidative stress.

Authors:  Karl-Rudolf Erlemann; Chantal Cossette; Sylvie Gravel; Alain Lesimple; Gue-Jae Lee; Goutam Saha; Joshua Rokach; William S Powell
Journal:  Free Radic Biol Med       Date:  2006-12-14       Impact factor: 7.376

4.  Superoxide production by human eosinophils can be inhibited in an agonist-selective manner.

Authors:  M K Bach; J R Brashler; E N Petzold; M E Sanders
Journal:  Agents Actions       Date:  1992-01

5.  C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation.

Authors:  P J Daffern; P H Pfeifer; J A Ember; T E Hugli
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

Review 6.  Eosinophils in the pathogenesis of allergic airways disease.

Authors:  S G Trivedi; C M Lloyd
Journal:  Cell Mol Life Sci       Date:  2007-05       Impact factor: 9.261

7.  Differential cytokine expression of human retinal pigment epithelial cells in response to stimulation by C5a.

Authors:  Y Fukuoka; M Strainic; M E Medof
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

8.  FMLP is a potent activator of guinea-pig eosinophils but its activity is dependent on the prior overnight in vitro culture of the cells (facilitation).

Authors:  M K Bach; J R Brashler
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

9.  Novel highly potent OXE receptor antagonists with prolonged plasma lifetimes that are converted to active metabolites in vivo in monkeys.

Authors:  Qiuji Ye; Shishir Chourey; Chintam Nagendra Reddy; Rui Wang; Chantal Cossette; Sylvie Gravel; Irina Slobodchikova; Dajana Vuckovic; Joshua Rokach; William S Powell
Journal:  Br J Pharmacol       Date:  2020-01-17       Impact factor: 8.739

10.  Eosinophils in fungus-associated allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.